Kidney Cancer PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting kidney cancer. PDX models are known to be the most predictive preclinical model and provide an accurate approach to evaluating an agent’s efficacy prior to entering the clinic. The CrownBio kidney cancer PDX collection consists of several models, including models from both North American and Asian descent. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
KI0326 CCRCCCLICK TO VIEW
KI0551 TCCCLICK TO VIEW
KI10101 NACLICK TO VIEW
KI10102 NACLICK TO VIEW
KI10105 RCCCLICK TO VIEW
KI10106 RCCCLICK TO VIEW
KI10115 NACLICK TO VIEW
KI11409 NACLICK TO VIEW
KI1410 RCCCLICK TO VIEW
KI16031 NACLICK TO VIEW
KI2361 CCRCCCLICK TO VIEW
KI2367 RCCCLICK TO VIEW
KI2368 RCCCLICK TO VIEW
KI2389 CCRCCCLICK TO VIEW
KI2407 RCCCLICK TO VIEW
KI2430 SCCCLICK TO VIEW
KI2432 NACLICK TO VIEW
KI2479 CCRCCCLICK TO VIEW
KI2552 NACLICK TO VIEW
KI9309 NACLICK TO VIEW